

## Press Release

June 9, 2020

### Change of Certified Adviser to Redeye AB

**2cureX AB (“2cureX”) has entered into an agreement with Redeye AB regarding Certified Adviser services. Redeye AB will be appointed as Certified Adviser on the 15<sup>th</sup> of June 2020. Until the 15<sup>th</sup> of June 2020, Svensk Kapitalmarknadsgrensning AB will continue to act as Certified Adviser for the company.**

#### For more information about 2cureX:

Ole Thastrup, Chief Executive Officer  
E-mail: [ot@2curex.com](mailto:ot@2curex.com)  
Telephone: +45 22 11 53 99  
[www.2curex.com](http://www.2curex.com)

#### Certified Adviser

Svensk Kapitalmarknadsgrensning AB  
Telephone: +46 (0) 70 – 755 95 51  
E-mail: [ca@skmg.se](mailto:ca@skmg.se)

#### Certified Adviser (starting on the 15<sup>th</sup> of June 2020)

Redeye AB  
Telephone: +46 8 121 576 90  
E-mail: [certifiedadviser@redeye.se](mailto:certifiedadviser@redeye.se)

---

#### About 2cureX

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).